1 in 3 Bharat Biotech Covaxin takers reported adverse events, finds BHU study

In light of growing concerns about COVID-19 vaccine safety, a comprehensive one-year follow-up study by Banaras Hindu University (BHU) researchers sheds light on the long-term effects of Bharat Biotech's Covaxin. This study aimed to assess adverse events of special interest (AESI) among vaccine recipients, providing crucial insights into the vaccine's safety profile.

The study included 635 adolescents and 291 adults, revealing that nearly one-third of the participants reported AESI. Among adolescents, common AESIs included new-onset skin and subcutaneous disorders (10.5%), general disorders (10.2%), and nervous system disorders (4.7%). In adults, the prevalent AESIs were general disorders (8.9%), musculoskeletal disorders (5.8%), and nervous system disorders (5.5%). Serious AESIs, such as stroke and Guillain-Barre syndrome, were reported in 1% of participants.